The Migraine Treatment Access Problem
Today, we’re discussing one of the biggest roadblocks to treatment for the condition: access.
The Reality of Living with Migraine
Migraine is a debilitating neurological disorder impacting over a billion people worldwide.
Patrick Dempsey, Pfizer and the American Cancer Society Team Up to “Change the Odds” Against Cancer
For award-winning actor and cancer community advocate Patrick Dempsey, working to help make sure everyone has the same opportunity to prevent, detect and treat cancer is deeply personal.
September Social Media Round-Up—Health Equity, Digital Hackathon, and More
Pfizer kicked off back-to-school season with another eventful month.
Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B
- If approved in Europe, marstacimab is expected to become the first once-weekly subcutaneous treatment for people living with severe hemophilia B and the first to be administered via a pre-filled pen for people living with severe hemophilia A or B
NEW YORK, September 20, 2024 – Pfizer Inc.
Pfizer Wraps Up 8th Year of Immersive Girls Who Code Program
From July 29th to August 9th, Pfizer hosted its 8th Summer Immersion Program in partnership with Girls Who Code (GWC). Throughout the event, more than 60 students participated in colleague-led learning sessions on professional development, data science, cybersecurity, and more.
August Social Media Round-Up—the Summer Games, Girls Who Code, and More
Pfizer closed out the summer months with a splash. Check out our monthly round up for more!
PfizerForAll Strives to Simplify How You Access Healthcare
It’s not breaking news to say that healthcare in the U.S. is complicated.
The ABCs (and WYs) of Meningococcal Meningitis
As you prepare your kids for a new year, it’s important to help protect their health from the myriad germs and viruses that spread throughout fall and winter.
Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price
NEW YORK, August 15, 2024 — Pfizer Inc. (NYSE: PFE) today announced that on August 15, 2024, the U.S. Department of Health and Human Services released the “maximum fair price” (MFP) for ELIQUIS® (apixaban), which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA). The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00.